IP Library › Granted Patent US 8,222,390
Granted Patent B2
US 8,222,390 · App. 12/749,012 · Granted Jul 17, 2012

Biomarkers for inflammatory bowel disease and irritable bowel syndrome

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,222,390
App. No.
12/749,012
Granted
Jul 17, 2012
Kind
B2
Abstract

The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome.

Claims (26)

1. A biomarker consisting of between 4 and 35 different nucleic acid probe sets, wherein:

(a) a first probe set consists of one or more nucleotide probes consisting of 15 or more contiguous nucleotides of SEQ ID NO:3(BLCAP), or a full complement thereof;

(b) a second probe set consists of one or more nucleotide probes consisting of 15 or more contiguous nucleotides of SEQ ID NO:4 (TH1L), or a full complement thereof;

(c) a third probe set consists of one or more nucleotide probes consisting of 15 or more contiguous nucleotides of SEQ ID NO:9 (HIST1H2BK), SEQ ID NO:3 (BLCAP), or a full complement thereof; and

(d) a fourth probe set consists of one or more nucleotide probes consisting of 15 or more contiguous nucleotides of one of SEQ ID NO:5 (UBE2G1) or SEQ ID NO:6 (CALM3), or a full complement thereof;

wherein each of the between 4 and 35 different probe sets consists of one or more probes of 15 or more contiguous nucleotides, or full complements thereof, of a different mRNA, and wherein each of the different probe sets is optionally detectably labeled.

2. The biomarker of claim 1 , wherein the first probe set consists of one or more nucleotide probes of 15 or more contiguous nucleotides of SEQ ID NO:3 (BLCAP), or a full complement thereof; the second probe set consists of one or more nucleotide probes of 15 or more contiguous nucleotides of SEQ ID NO:4 (TH1L), or a full complement thereof; the third probe set consists of one or more nucleotide probes of 15 or more contiguous nucleotides of SEQ ID NO:9 (HIST1H2BK), or a full complement thereof; and the fourth probe set consists of one or more nucleotide probes of 15 or more contiguous nucleotides of SEQ ID NO:5 (UBE2G1), or a full complement thereof.

3. The biomarker of claim 2 , wherein the biomarker consists of between 4 and 25 probe sets.

4. The biomarker of claim 2 , wherein the biomarker consists of between 4 and 10 probe sets.

5. The biomarker of claim 2 , wherein the biomarker consists of between 4 and 5 probe sets.

6. A biomarker consisting of between 4 and 35 different nucleic acid primer pairs, wherein:

(a) a first primer pair is capable of selectively amplifying a detectable portion of SEQ ID NO:3 (BLCAP), wherein each primer in the first primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:3 (BLCAP), or a full complement thereof;

(b) a second primer is pair capable of selectively amplifying a detectable portion of SEQ ID NO:4 (TH1L), wherein each primer in the second primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:4 (TH1L), or a full complement thereof;

(c) a third primer pair is capable of selectively amplifying a detectable portion of SEQ ID NO:9 (HIST1H2BK), wherein each primer in the third primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:9 (HIST1H2BK), or a full complement thereof; and

(d) a fourth primer pair is capable of selectively amplifying a detectable portion of one of SEQ ID NO:5 (UBE2G1) or SEQ ID NO:6 (CALM3), wherein each primer in the fourth primer pair consists of 15 or more contiguous nucleotides of a nucleic acid selected from one of SEQ ID NO:5 (UBE2G1) or SEQ ID NO:6 (CALM3), or a full complement thereof;

wherein each of the between 4 and 35 different primer pairs consists of one or more primer pairs, wherein each primer consists of 15 or more contiguous nucleotides, or full complements thereof, for a different mRNA, and wherein each of the different primer pairs is optionally detectably labeled.

7. The biomarker of claim 6 , wherein each primer in the first primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:3 (BLCAP), or a full complement thereof; each primer in the second primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:4 (TH1L), or a full complement thereof; each primer in the third primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:9 (HIST1H2BK), or a full complement thereof; and each primer in the fourth primer pair consists of 15 or more contiguous nucleotides of SEQ ID NO:5 (UBE2G1), or a full complement thereof.

8. The biomarker of claim 7 , wherein the biomarker consists of between 4 and 25 primer pairs.

9. The biomarker of claim 7 , wherein the biomarker consists of between 4 and 10 primer pairs.

10. The biomarker of claim 7 , wherein the biomarker consists of between 4 and 5 primer pairs.

11. The biomarker of claim 1 , wherein the biomarker consists of between 4 and 25 probe sets.

12. The biomarker of claim 1 , wherein the biomarker consists of between 4 and 10 probe sets.

13. The biomarker of claim 1 , wherein the biomarker consists of between 4 and 5 probe sets.

14. The biomarker of claim 6 , wherein the biomarker consists of between 4 and 25 primer pairs.

15. The biomarker of claim 6 , wherein the biomarker consists of between 4 and 10 primer pairs.

16. The biomarker of claim 6 , wherein the biomarker consists of between 4 and 5 primer pairs.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Sep 4, 2025
From: NEW MEXICO MEZZANINE PARTERSN, L.P.; NEW MEXICO CO-INVESTMENT FUND, L.P.
To: EXAGEN INC.
Reel/Frame 072159/0497 →
SECURITY INTEREST Recorded Apr 25, 2025
From: EXAGEN INC.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 070952/0802 →
RELEASE OF SECURITY INTEREST Recorded Sep 7, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: EXAGEN DIAGNOSTICS, INC.
Reel/Frame 043784/0828 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Oct 15, 2013
From: EXAGEN DIAGNOSTICS, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031414/0660 →
SECURITY AGREEMENT Recorded Nov 4, 2010
From: EXAGEN DIAGNOSTICS, INC.
To: NEW MEXICO MEZZANINE PARTNERS, L.P.; NEW MEXICO CO-INVESTMENT FUND, L.P.
Reel/Frame 025317/0170 →
SECURITY AGREEMENT Recorded Sep 23, 2010
From: EXAGEN DIAGNOSTICS, INC.
To: LOS ALAMOS NATIONAL BANK
Reel/Frame 025227/0471 →